Breaking News, Collaborations & Alliances

Duke, GenScript, A*STAR Enter COVID-19 Pact

Launch SARS-CoV-2 serology test to detect neutralizing antibodies without need of containment facility or specimen

By: Contract Pharma

Contract Pharma Staff

Duke-NUS Medical School, a research intensive graduate-entry medical school, along with the biotech GenScript and the Diagnostics Development Hub (DxD) at Singapore’s Agency for Science, Technology and Research (A*STAR), have entered an agreement to co-develop and manufacture a serological coronavirus (COVID-19) detection system known as the surrogate virus neutralization test (sVNT) or cPass. This test is the first in the world that allows rapid detection of neutralizing antibodies (NAbs)...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters